An evaluation of site-specific immune responses directed against first-generation adenoviral vectors administered by convection-enhanced delivery

Journal of Gene Medicine

Volumn 13, Issue 5, 2011, Pages 269-282

  White, Edward ^a,b   Bienemann, Alison ^b   Taylor, Hannah ^b   Castrique, Emma ^b   Bunnun, Chotirote ^b   Wyatt, Marcella ^b   Gill, Steven ^a,b  

^a FRENCHAY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Adenovirus; Convection enhanced delivery; Large animal model; Malignant glioma

Indexed keywords

ADENOVIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; ASTROCYTOSIS; BRAIN; CONTROLLED STUDY; CORPUS STRIATUM; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; INFUSION; MALE; NERVE CELL; NONHUMAN; PLAQUE FORMING CELL; PRIORITY JOURNAL; RAT; TISSUE INJURY; TOXICITY; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; WHITE MATTER;

ADENOVIRIDAE; ANIMALS; BRAIN; CONVECTION; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; INFUSIONS, INTRAVENOUS; MALE; MICROGLIA; RATS; RATS, WISTAR; SWINE; TRANSDUCTION, GENETIC; VIRAL TROPISM;

ADENOVIRIDAE; ANIMALIA; RATTUS;

EID: 79958116638     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1567     Document Type: Article

References (31)

1. Anderson RD, Haskell RE, Xia H, et al. A simple method for the rapid generation of recombinant adenovirus vectors. Gene Ther 2000; 7: 1034-1038.
2. Chiocca EA, Smith KM, McKinney B, et al. A phase I trial of Ad.hIFN-beta gene therapy for glioma. Mol Ther 2008; 16: 618-626.
3. Eck SL, Alavi JB, Judy K, et al. Treatment of recurrent or progressive malignant glioma with a recombinant adenovirus expressing human interferon-beta (H5. 010CMVhIFN-beta): a phase I trial. Hum Gene Ther 2001; 12: 97-113.
4. Sanftner LM, Sommer JM, Suzuki BM, et al. AAV2-mediated gene delivery to monkey putamen: evaluation of an infusion device and delivery parameters. Exp Neurol 2005; 194: 476-483.
5. Thomas CE, Schiedner G, Kochanek S, et al. Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chronic diseases. Proc Natl Acad Sci USA 2000; 97: 7482-7487.
6. White E, Bienemann A, Sena-Esteves M, et al. Evaluation and optimization of the administration of recombinant adeno-associated viral vectors (serotypes 2/1, 2/2, 2/rh8, 2/9, and 2/rh10) by convection-enhanced delivery to the striatum. Hum Gene Ther 2011; 22: 237-251.
7. White E, Woolley M, Bienemann A, et al. A robust MRI-compatible system to facilitate highly accurate stereotactic administration of therapeutic agents to targets within the brain of a large animal model. J Neurosci Methods 2011; 195: 78-87.
8. Mitchell P. Ark's gene therapy stumbles at the finish line. Nat Biotechnol 2010; 28: 183-184.
9. Behin A, Hoang-Xuan K, Carpentier AF, et al. Primary brain tumours in adults. Lancet 2003; 361: 323-331.
10. Hess CF, Schaaf JC, Kortmann RD, et al. Malignant glioma: patterns of failure following individually tailored limited volume irradiation. Radiother Oncol 1994; 30: 146-149.
11. Lang FF, Bruner JM, Fuller GN, et al. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol 2003; 21: 2508-2518.
12. Bobo RH, Laske DW, Akbasak A, et al. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 1994; 91: 2076-2080.
13. Chen MY, Hoffer A, Morrison PF, et al. Surface properties, more than size, limiting convective distribution of virus-sized particles and viruses in the central nervous system. J Neurosurg 2005; 103: 311-319.
14. Thomas CE, Birkett D, Anozie I, et al. Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlate with decreased vector-mediated transgene expression in the brain. Mol Ther 2001; 3: 36-46.
15. White EA, Bienemann AS, Megraw L, et al. Evaluation and optimisation of the administration of a selectively replicating herpes simplex viral vector to the brain by convection-enhanced delivery. Cancer Gene Ther 2011; 18: 358-369.
16. Peltekian E, Parrish E, Bouchard C, et al. Adenovirus-mediated gene transfer to the brain: methodological assessment. J Neurosci Methods 1997; 71: 77-84.
17. Sanftner LM, Suzuki BM, Doroudchi MM, et al. Striatal delivery of rAAV-hAADC to rats with preexisting immunity to AAV. Mol Ther 2004; 9: 403-409.
18. Vite CH, Passini MA, Haskins ME, et al. Adeno-associated virus vector-mediated transduction in the cat brain. Gene Ther 2003; 10: 1874-1881.
19. Bankiewicz KS, Eberling JL, Kohutnicka M, et al. Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol 2000; 164: 2-14.
20. Brust D, Feden J, Farnsworth J, et al. Radiosensitization of rat glioma with bromodeoxycytidine and adenovirus expressing herpes simplex virus-thymidine kinase delivered by slow, rate-controlled positive pressure infusion. Cancer Gene Ther 2000; 7: 778-788.
21. Betz AL, Shakui P, Davidson BL. Gene transfer to rodent brain with recombinant adenoviral vectors: effects of infusion parameters, infectious titer, and virus concentration on transduction volume. Exp Neurol 1998; 150: 136-142.
22. ter Horst M, Verwijnen SM, Brouwer E, et al. Locoregional delivery of adenoviral vectors. J Nucl Med 2006; 47: 1483-1489.
23. Chen H, Brook MA, Chen Y, et al. Surface properties of PEO-silicone composites: reducing protein adsorption. J Biomater Sci Polym 2005; 16: 531-548.
24. Detrait ER, Bowers WJ, Halterman MW, et al. Reporter gene transfer induces apoptosis in primary cortical neurons. Mol Ther 2002; 5: 723-730.
25. Hermens WT, Verhaagen J. Suppression of inflammation by dexamethasone prolongs adenoviral vector-mediated transgene expression in the facial nucleus of the rat. Brain Res Bull 1998; 47: 133-140.
26. Puntel M, Kroeger KM, Sanderson NS, et al. Gene transfer into rat brain using adenoviral vectors. Curr Protoc Neurosci 2010; 4: 24.
27. Puntel M, Muhammad AK, Candolfi M, et al. A novel bicistronic high-capacity gutless adenovirus vector that drives constitutive expression of herpes simplex virus type 1 thymidine kinase and tet-inducible expression of Flt3 l for glioma therapeutics. J Virol 2010; 84: 6007-6017.
28. Muhammad AK, Puntel M, Candolfi M, et al. Study of the efficacy, biodistribution, and safety profile of therapeutic gutless adenovirus vectors as a prelude to a phase I clinical trial for glioblastoma. Clin Pharmacol Ther 2010; 88: 204-213.
29. Pluhar GE, Grogan PT, Seiler C, et al. Anti-tumor immune response correlates with neurological symptoms in a dog with spontaneous astrocytoma treated by gene and vaccine therapy. Vaccine 2010; 28: 3371-3378.
30. Pope IM, Poston GJ, Kinsella AR. The role of the bystander effect in suicide gene therapy. Eur J Cancer 1997; 33: 1005-1016.
31. Maatta AM, Samaranayake H, Pikkarainen J, et al. Adenovirus mediated herpes simplex virus-thymidine kinase/ganciclovir gene therapy for resectable malignant glioma. Curr Gene Ther 2009; 9: 356-367.